ArticlePloS one2026
Enhanced ganoderic acids production by using thermotolerant Ganoderma tsugae at high-temperature liquid cultivation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ganoderic acids (GAs) are bioactive triterpenoids produced by Ganoderma species with demonstrated anticancer properties. While the yield of GAs in Ganoderma tsugae is typically low, heat stress has been shown to enhance its production. This study employed atmospheric and room temperature plasma (ARTP) mutagenesis to develop thermotolerant G. tsugae mutants for high-temperature cultivation at 35°C. From 59 mutants generated, strain Ganoderma tsugae 9 (GT9) demonstrated superior thermotolerance, showing 51.48% increased mycelial growth rate and 76.03% higher biomass compared to wild-type (WT) at 35°C (one-way ANOVA with Dunnett's test, p < 0.05). Physiological characterization revealed GT9 possessed enhanced membrane fluidity, elevated intracellular levels of lanosterol (92.49% increase), squalene (1.36-fold increase), trehalose, and ergosterol (66.98% increase) (two-way ANOVA with Tukey's test, p < 0.05). Transcriptional analysis revealed significant upregulation of key GAs biosynthetic genes (hmgr, sqs, se, ls) and heat shock protein genes (hsp17.4, hsp22, hsp70, hsp90). After 10-day cultivation at 35°C, GT9 produced 1.01-fold more GAs than the WT at 35°C and 22.64% more than the WT at 25°C (two-way ANOVA with Tukey's test, p < 0.05). However, the difference in GAs production between the WT strain cultured at 25°C and the GT9 strain cultured at 35°C was not significant. ARTP-generated thermotolerant G. tsugae mutants enable efficient high-temperature fermentation for enhanced GAs production. This strategy provides significant advantages for industrial-scale application while elucidating the physiological and molecular mechanisms underlying improved GAs biosynthesis under heat stress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.